Improving Early Detection of Liver Cancer in Patients with Cirrhosis or Hepatitis B
NCT06084234 · RecruitingThis trial is looking at how well two methods work for screening liver cancer in patients with cirrhosis or chronic hepatitis B. One method uses ultrasound and a blood test called AFP. The other method uses a different blood test called GALAD. The goal is to see which method better helps find liver cancer at an early stage and reduces late-stage cases over time.
Locations and contact
This trial is running at 18 locations in the United States. 17 of them are currently recruiting.
United States18 locations · 17 recruiting
- Baylor College of MedicineHouston, TexasRecruiting
- Case Western Reserve UniversityCleveland, OhioRecruiting
- Hennepin HealthcareMinneapolis, MinnesotaRecruiting
- Henry Ford Health SystemDetroit, MichiganRecruiting
- Indiana UniversityIndianapolis, IndianaRecruiting
- Kaiser PermanenteRoseville, CaliforniaRecruiting
- Massachusetts General HospitalBoston, MassachusettsRecruiting
- Northwestern UniversityChicago, IllinoisRecruiting
- Stanford UniversityRedwood City, CaliforniaRecruiting
- The Feinstein Institutes, Northwell Health, Inc.Manhasset, New YorkRecruiting
- University of California, San FranciscoSan Francisco, CaliforniaRecruiting
- University of MichiganAnn Arbor, MichiganRecruiting
- University of MinnesotaMinneapolis, MinnesotaRecruiting
- University of North CarolinaChapel Hill, North CarolinaRecruiting
- University of PennsylvaniaPhiladelphia, PennsylvaniaRecruiting
- University of Southern CaliforniaLos Angeles, CaliforniaRecruiting
- UT Southwestern Medical Center and Parkland HospitalDallas, TexasRecruiting
- Virginia Commonwealth UniversityRichmond, VirginiaNot Yet Recruiting
Who can join
Adults aged 18 to 85 with cirrhosis or chronic hepatitis B can join. They need to be evaluated by a doctor to ensure they qualify. Some people may not be able to join, including those with certain health conditions or a history of other cancers. The trial team will confirm who is eligible.
What happens during the trial
Participants will be placed into two groups by chance. One group will have regular ultrasound screenings, with or without the AFP blood test. The other group will have the GALAD blood test every six months. This will continue for several years, and follow-up tests will be offered based on their assigned group.
The trial team
The trial is led by the University of Texas Southwestern Medical Center, with support from several partners including the National Cancer Institute and other universities. Dr. Amit Singal is the principal investigator overseeing the study.
Important dates
The trial started on December 26, 2023, and is currently recruiting new participants. It is expected to finish in December 2034, with the main analysis done by the end of 2029.
Additional information
The trial's ID number is NCT06084234. This is a Phase 4 trial, which means it is assessing how well the screening methods work and their safety. The trial aims to include about 5,500 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →